Inovio Pharmaceuticals Inc (INO)

[cameron12x]

OK, I stand corrected with regard to the hTERT trial. Here is the skinny, direct from Bernie at IR:

Our stated milestone is that a phase I will start in 2H 2014.

This product and trial have nothing to do with Roche, which licensed hep B and prostate.

We’re also looking forward to seeing this third product in our “cancer portfolio” move into a human study. It will be another step toward the overall process that we have spoken about: at the R&D level we are in identifying and will advance an even broader set of antigen targets that we believe offer significant potential in different combinations to target virtually all cancers. There are typically multiple possible antigens related to any particular cancer (or infectious disease, for that matter). (Antigens are simply proteins associated with a particular cancer or infectious disease that the immune system can recognize as being “foreign.”) Different antigens are associated with different cancers and, like hTERT, certain antigens are associated to greater or less degrees to multiple cancers. So when we design the individual DNA plasmid “constructs” that contain the code, or instructions, to produce a specific antigen in the body, we can mix and match them to create an optimal set of targets to activate T cells against a particular cancer.

Achieving the efficacy proof of concept for our technology with the phase II data was an historical step for our technology, our company, and the field. It’s onward and upward. From here.